➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKesson
Baxter
Dow
Harvard Business School

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

Litigation Details for American Sales Company, Inc. v. Novo Nordisk A/S (E.D. Mich. 2010)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

American Sales Company, Inc. v. Novo Nordisk A/S (E.D. Mich. 2010)

Docket   Start Trial Date Filed 2010-05-28
Court District Court, E.D. Michigan Date Terminated 2015-01-20
Cause 15:25 Clayton Act Assigned To Avern Levin Cohn
Jury Demand Plaintiff Referred To Donald a. Scheer
Parties AMBER LAMBERT; AMERICAN SALES COMPANY, INC.; JONATHON RICH; NOVO NORDISK A/S; NOVO NORDISK, INCORPORATED; ROCHESTER DRUG CO-OPERATIVE, INC.; TIMMY K. LOUGHNER
Patents 6,677,358; RE37,035
Attorneys Amber Lambert; Andrew C. Curley - NOT SWORN; Ashley E. Johnson; Ashley E. Johnson - NOT SWORN; David A. Ettinger; David B. Tulchin; Eric L. Cramer - NOT SWORN; Herschel P. Fink; J. Douglas Richards; Jonathon Rich; Marc De Leeuw; Michael A. Sitzman; Michael S. Royall; Patrick E. Cafferty; Timmy K. Loughner
Firms Amber Lambert; Berger & Montague PC; Berger & Montague, P.C.; Gibson Dunn and Crutcher LLP; Jonathon Rich; Timmy K. Loughner
Link to Docket External link to docket
Small Molecule Drugs cited in American Sales Company, Inc. v. Novo Nordisk A/S
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for American Sales Company, Inc. v. Novo Nordisk A/S (E.D. Mich. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-05-28 1 by assignment of United States Patent No. 6,677,358 (“the ‘358 patent”). 15. Defendant Novo…in September 2006; and (3) U.S. Patent No. 6,677,358 (“the ‘358 patent”), entitled “NIDDM REGIMEN”, which…Novo Nordisk also listed U.S. Pat. No. 6,677,358 (“the ‘358 patent”), entitled “NIDDM REGIMEN”, which issued…to Obtain the ‘358 Patent 80. The ’358 patent issued from U.S. Patent Application No. 09/…challenge the compound patent, but included a certification that the ‘358 patent was either invalid or External link to document
2010-08-30 18 by assignment of United States Patent No. 6,677,358 (“the ’358 patent”). 29. Defendant Novo…in September 2006; and (3) U.S. Patent No. 6,677,358 (“the ’358 patent”), entitled “NIDDM REGIMEN,” which…Novo Nordisk also listed U.S. Pat. No. 6,677,358 (“the ’358 patent”), entitled “NIDDM REGIMEN,” which issued…compound patent that Defendants listed in the Orange Book, but did certify that the ’358 patent was invalid… with the patent infringement action, Caraco has asserted, inter alia, that the ’358 patent is unenforceable External link to document
2010-12-29 32 code narrative for U.S. Patent No. 6,677,358 (the “‘358 patent”) to track an amendment …acquired the ‘358 patent through fraud on the Patent and Trademark Office… manipulating the patent use code narrative for Novo’s ‘358 patent to cover the two …two non- patented uses, as well as the one patented use, of repaglinide…drug that did not violate the ‘358 patent. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Boehringer Ingelheim
McKesson
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.